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DOI 10.1016/j.ccr.2010.05.024SUMMARYNeuroendocrine (NE) phenotype, seen in >30% of prostate adenocarcinomas (PCa), and NE prostate tumors
are implicated in aggressive prostate cancer. Formation of NE prostate tumors in the TRAMP mouse model
was suppressed in mice lacking the ubiquitin ligase Siah2, which regulates HIF-1a availability. Cooperation
between HIF-1a and FoxA2, a transcription factor expressed in NE tissue, promotes recruitment of p300 to
transactivate select HIF-regulated genes, Hes6, Sox9, and Jmjd1a. These HIF-regulated genes are highly
expressed in metastatic PCa and required for hypoxia-mediated NE phenotype, metastasis in PCa, and
the formation of NE tumors. Tissue-specific expression of FoxA2 combined with Siah2-dependent HIF-1a
availability enables a transcriptional program required for NE prostate tumor development and NE phenotype
in PCa.INTRODUCTION
Prostate cancer is the second leading cause of cancer deaths
among men in Western nations. Among the metastatic forms
of prostate adenocarcinoma (PCa) are those that express neuro-
endocrine (NE) markers, often referred to as neuroendocrine
differentiation (NED) or NE phenotype. NED is seen in >30% of
PCa and is associated with poor prognosis and androgen inde-
pendence (Cindolo et al., 2007). A small percentage (0.5%–2%)
of human prostate tumors develop as highly aggressive NE
tumors, which have a 35% survival rate in 2 years (Cindolo
et al., 2007; Sella et al., 2000). Factors implicated in NED of
LNCaP prostate cancer cells in vitro include IL-6 treatmentSignificance
Prostate adenocarcinomas (PCa) with neuroendocrine (NE) ph
prognosis and androgen independence. Here, we demonstrate
the ubiquitin ligase Siah2. Through its role in the control of HIF
and the NE-specific transcription factor FoxA2. Genes induced
and in metastatic human PCa and required for formation of th
development of NE tumors. Tissue-specific cooperation betw
prostate tumor development offers a paradigm for the devel
prostate tumors.(Deeble et al., 2001), androgen removal (Yuan et al., 2006), and
ionizing radiation (Deng et al., 2008). In transgenic animals, T
antigen expression or inactivation of p53 and Rb has been asso-
ciated with prostate NE tumors (Huss et al., 2007; Zhou et al.,
2006).
FoxA2, a member of the FoxA subfamily of Forkhead box tran-
scription factor, is expressed in mouse prostate NE carcinomas
(Chiaverotti et al., 2008; Mirosevich et al., 2006) and NE foci of
human PCa (Mirosevich et al., 2006). HIF-1a, the master regu-
lator of the hypoxia response, is also expressed in NE tumors
(Monsef et al., 2007). HIF-1a is regulated under normoxia by
the E3 ligase pVHL and is also regulated under mild hypoxia
(2%–5% O2) by the ubiquitin ligase Siah2. Siah2 controls prolylenotype and NE prostate tumors are associated with poor
that formation of NE tumors and metastasis of PCa require
-1a availability, Siah2 enables cooperation between HIF-1a
by HIF-1a/FoxA2 cooperation are expressed in NE lesions
e NE phenotype, for metastasis of human PCa, and for the
een transcription factors that promote NE phenotype and
opment, progression, and potential targeting of aggressive
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Figure 1. Tumorigenesis in TRAMPTg/Siah2 Mice
(A) Primary tumor incidences of TRAMP mice with indicated Siah2 genotype are shown as percentages.
(B) Typical H&E staining of neuroendocrine carcinoma (NE) derived from TRAMP/Siah2+/ and AH derived from TRAMP/Siah2/ mice.
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Siah2, FoxA2, and HIF-1a in Prostate Cancerhydroxylase 1/3 (PHD) stability (Nakayama et al., 2004), thereby
affecting PHD availability to modify HIF-1a, which is essential for
HIF-1a’s association with and ubiquitination by pVHL (Ivan et al.,
2001). Given that PHD functions as cellular oxygen sensors
(Aragones et al., 2009; Nakayama et al., 2009), Siah2 is expected
to play a central role in controlling hypoxia and related biological
outcomes, including tumorigenesis and metastasis (Nakayama
et al., 2009). Indeed, inhibition of Siah2 activity blocks formation
of tumors (Ahmed et al., 2008; Moller et al., 2009; Qi et al., 2008;
Schmidt et al., 2007). Further, Siah2’s contribution to melanoma
metastasis is HIF dependent (Qi et al., 2008).
Once stabilized, HIF-1a translocates to the nucleus and
dimerizes with HIF-1b; the heterodimers then bind to hypoxia
responsive elements (HREs) to regulate transcription of hypoxia-
responsive genes (Semenza, 2003). Several transcription fac-
tors cooperate with HIF to regulate its transcriptional activity;
HIF activity is enhanced by b-catenin (Kaidi et al., 2007) and
repressed by FOXO3a (Emerling et al., 2008). HIF can also modu-
late activity of other transcriptional regulators: HIF-1apotentiates
Notch signaling (Gustafsson et al., 2005) and represses c-Myc
activity (Zhang et al., 2007).
Given the role of Siah2 in regulation of HIF-1a, we set to deter-
mine its role in prostate cancer development and metastasis.
RESULTS
Attenuated Formation of Prostate NE Carcinoma
in Siah2 Null TRAMPMice
We employed the TRAMP mouse model, in which prostate-
specific expression of SV40 T antigen results in prostate tumors
that metastasize to lymph nodes, lung, and liver (Gingrich et al.,
1996), to assess the possible role of Siah in tumor growth and
metastasis. Analysis of 8-month-old TRAMP mice with different
Siah2 background (TRAMP/Siah2/, TRAMP/Siah2+/, and
TRAMP/Siah2+/+) revealed that the majority developed prostate
masses (Figure 1A). Most primary masses were composed of
benign proliferations of stroma and epithelium with atypical
epithelial hyperplasia (AH) in TRAMP/Siah2/ mice, compared
with a preponderance of NE carcinoma in the TRAMP/Siah2+/
and TRAMP/Siah2+/+ mice (Figures 1B and 1C). Although
TRAMP AH have been referred to as adenocarcinoma in some
literature (e.g., Gingrich et al., 1996), we refer them as TRAMP
AH in lieu of clear discrimination, detailed in Chiaverotti et al.,
(2008). NE carcinomas were identified by morphology (Fig-
ure 1B) and expression of the well-established NE markers
synaptophysin, neuron-specific enolase (NSE), and FoxA2
(Figure 1D), consistent with the notion that the TRAMP tumors
are primarily of NE origin (Chiaverotti et al., 2008). In clear(C) Incidence of NE and AH in TRAMP mice with indicated Siah genotypes. Numb
for NE tumor incidence between control and Siah-deficient TRAMP mice.
(D) IHC analyses of primary NE carcinoma with indicated genotypes using the in
(E) NSE and FoxA2 staining of the NE tumor foci of 5-month-old TRAMP mice.
(F) IHC staining of CD31 in NE carcinomas from mice of indicated genotypes.
(G) Re-expression of HIF-1a in PHYL-expressing TRAMP-C cells. Cells were stab
further stably transfected with HIF-1a and maintained in normoxia (N) or hypoxia
(H and I) TRAMP-C cells (3 3 106) expressing control pKH3 vector, PHYL, o
The frequency of tumor formation (H) and size of xenograft tumor (I) 8-weeks p
deviation) for five mice, p < 0.05 for pKH3 versus PHYL+HIF-1a. See also Figurecontrast, FoxA2, synaptophysin, and NSE were undetectable
in normal prostate glands (Figure 1D, arrows) or in AH (data
not shown).
Since Siah1 also contributes to the regulation of PHD and
consequently HIF availability (Nakayama et al., 2004; Qi et al.,
2008), we also evaluated Siah1a function in prostate tumor
formation. Siah2 and Siah1a doubly homozygous mutant mice
are non-viable (Frew et al., 2003). We therefore established
a TRAMP/Siah1a+/Siah2/ mouse line. TRAMP/Siah1a+/
Siah2/ mice showed a prostate tumor incidence similar to
that seen in TRAMP/Siah2/ mice (Figure 1A) but lacked NE
tumors (Figure 1C).
In the TRAMP mice, the early NE tumor lesions develop in the
ventral prostate after 3 months and are recognized as foci that
express NE markers. To examine the effect of Siah2 on the
development of early stage NE tumors, we analyzed 5-month-
old mice. NE foci were identified in three of six control mice
but in none of the ten TRAMP/Siah2/ mice (Figure 1E;
the difference is statistically significant). These data reveal that
in the TRAMP model Siah is required for development of NE
carcinomas.
AH predominantly develops in the dorsal lateral lobe of pros-
tate and is identifiable in 1-month-old TRAMP mice (Chiaverotti
et al., 2008). To evaluate whether Siah also involved in the
progression of AH, we analyzed the dorsal prostate lobes from
1- and 3-month-old mice and found that lack of Siah2 delayed
the progression from a normal prostate gland to the early and
medium stages AH in 1-month-old mice and into the late-stage
AH in the 3-month-old mice (Figures S1A and S1B available
online).
Altered HIF-1a Expression Correlates with Reduced Cell
Proliferation and Enhanced Cell Death in Primary NE
Tumor from TRAMP/Siah2/ Mice
Consistent with Siah2 regulation of HIF-1a availability, HIF-1a
level was reduced in the very few NE carcinomas observed
(Figure 1D) and in AH (Figure S1C) from TRAMP/Siah2/
mice compared with TRAMP/Siah2+/ mice. HIF-2a staining
was also reduced in AH from TRAMP/Siah2/ mice (Fig-
ure S1C), whereas HIF-2a was undetectable in NE carcinoma
from any genotype (data not shown). These findings are also
consistent with the observation that HIF-1a but not HIF-2a is
coexpressed with NE markers in prostate cancers (Monsef
et al., 2007).
Potential changes in proliferation, apoptosis, and angiogen-
esis were evaluated with PCNA, TUNEL/active caspase-3, and
CD31, respectively. NE tumors, but not AH, from TRAMP/
Siah2/ mice showed reduced cell proliferation and increaseder of mice for each genotype is indicated. Dark bars indicate NE+AH. p < 0.005
dicated antibodies. Arrows indicate normal prostate epithelial tissues.
ly transfected with indicated expression vectors. PHYL-expressing cells were
(H) for 6 hr before analyses by western blotting for HIF-1a.
r PHYL+HIF-1a were injected subcutaneously into the flanks of nude mice.
ostinjection are shown. In (I), each column represents mean ± SD (standard
S1 and Table S1.
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Siah2, FoxA2, and HIF-1a in Prostate Cancerapoptosis compared with those seen in TRAMP/Siah2+/ mice
(Figure 1D; Figure S1C; Table S1). Vascular density was similar
in the two strains in both the NE tumor (Figure 1F and Table S1)
and AH (Figure S1C and Table S1). Hence, loss of Siah and
consequent downregulation of HIF levels appear to specifically
govern proliferation and cell survival of NE tumors.
To directly assess a possible role for Siah2 and HIF-1a in
tumorigenesis of TRAMP cells, we analyzed TRAMP-C cells
derived from TRAMP tumors (Foster et al., 1997). These cells
likely represent NE tumor-derived cells as they express multiple
NE specific transcription factors (Figure 4A and data not shown).
The PHYL peptide binds to Siah’s substrate recognition site
(House et al., 2003) and attenuates Siah2’s effect on PHD1/3
and thus reduces HIF-1a levels under hypoxia (Moller et al.,
2009; Qi et al., 2008). Expression of the PHYL peptide in
TRAMP-C cells effectively abolished their ability to form tumors
(Figures 1H and 1I), consistent with the finding that NE tumors do
not form in TRAMP/Siah1a+/Siah2/ mice (Figure 1C). Forced
HIF-1a expression in TRAMP-C cells expressing PHYL peptide
by transfection (Figure 1G) partially recovered their ability to
form tumors (Figures 1H and 1I). These data support the role of
Siah2, in part through its regulation of HIF-1a levels, in formation
of NE prostate tumors.
Reduced Metastasis in TRAMP/Siah2/ Mice
Metastatic lesions in the liver, lung, and lymph nodes of TRAMP
mice were identified as NE carcinomas, based on morphology
(Figure 2A) and FoxA2/synaptophysin expression (Figure 2B).
However, both the frequency and size of metastatic lesions
were significantly reduced (6-fold) in the lung and were not found
in liver and lymph nodes of TRAMP/Siah2/ mice, compared
with TRAMP/Siah2+/ or TRAMP/Siah2+/+ animals (Figures 2A
and 2C). Furthermore, we found no metastases in TRAMP/
Siah1a+/Siah2/ mice (Figure 2C). The very few lung metas-
tases observed in TRAMP/Siah2/ mice were smaller, showed
reduced cell proliferation, and enhanced cell death (Figures 2D
and 2E). These findings point to the role of Siah2 in TRAMP tumor
metastasis.
FoxA2 Stimulates HIF Transcriptional Activity
Given that the NE-specific transcription factor FoxA2 is coex-
pressed with HIF-1a protein in nuclei of NE carcinoma cells
(Figure 1D), we tested the possibility that these transcription
factors cooperate with each other. While expression of exoge-
nous FoxA2 in TRAMP-C cells did not alter the expression of
an HRE-linked luciferase construct (HRE-Luc, data not shown),
expression of exogenous HIF-1a alone elicited a modest
increase in HRE-Luc activity as expected (Figure 3A). Signifi-
cantly, coexpression of HIF-1a and FoxA2 led to a 6-fold
increase in luciferase activity overexpression of HIF-1a aloneFigure 2. Metastasis in TRAMPTg/Siah2 Mice
(A) H&E staining of indicated tissues from TRAMP mice of indicated Siah2 genot
(B) Expression of NE markers in metastatic lesions of TRAMP/Siah2+/ mice rev
(C) Percentage of metastases in TRAMP mice with indicated Siah genotypes. N
9 (S1a+/:S2/) for liver and lung, and N = 26 (S2+/+ and S2+/), 11 (S2/), or 6
liver were examined by H&E staining.
(D) TUNEL staining (dark brown signals indicated by arrows) of lung sections fro
(E) IHC staining for PCNA on lung sections derived from TRAMP/Siah2+/ and T(Figure 3A). Coexpression of IPAS, a spliced form of HIF-3a
with potent dominant-negative activity toward all HIFs (Makino
et al., 2002), or inhibiting HIF-1a expression by expressing
S2RM (a dominant-negative form of Siah2) or PHYL abolished
FoxA2-potentiated HRE-Luc activity (Figure 3A). Importantly,
knockdown of FoxA2 caused a 40% reduction in HRE-Luc
activity under hypoxia, although the degree of inhibition was
lower than that seen with HIF-1a or HIF-1b siRNA (Figure 3B
and Figure S2A). These data establish a role for FoxA2 in
enhancing HIF-mediated transcriptional activity. In contrast,
HIF-1a did not stimulate FoxA2 transcription activity (data not
shown), indicating that HIF/FoxA2 transcriptional synergy may
be restricted to the context of an HRE. Notably, FoxA1 did not
increase HRE-Luc activity in the presence of HIF-1a (data not
shown).
We then mapped the FoxA2 domains required for cooperation
with HIF-1a. FoxA2 fragments consisting of the N-terminal trans-
activation domain (N-TAD), the central forkhead domain, or the
C-terminal transactivation domain (C-TAD) were generated and
evaluated for their effect on FOXA- and HIF-1a-dependent
transcription activity (Figure S2B). FoxA2 mutants lacking
either the N-TAD or C-TAD exhibited FOXA-dependent tran-
scriptional activity similar to that of the wild-type FoxA2 (Fig-
ure 3C), indicating that one transactivation domain is sufficient
for FoxA2 transcriptional activity. FoxA2 mutants lacking the
C-TAD promoted HIF-dependent transcriptional activity to a
level similar to wild-type FoxA2, whereas the FoxA2 mutant lack-
ing the N-TAD was much less effective (Figure 3D). The FoxA2
C terminus, which contains intrinsic chromatin remodeling
activity (Cirillo et al., 2002), was dispensable for HRE activation
(construct m-2 in Figure 3D; Figure S2B), thereby excluding the
role of chromatin remodeling activity in FoxA2 cooperation with
HIF. These data suggest that the N-TAD and forkhead domains
of FoxA2 are required to stimulate HIF-mediated transcriptional
activity.
HIF Interacts with FoxA2
Coexpression of HA-FoxA2 or HA-FoxA1 with Flag-HIF-1a in
293T cells followed by immunoprecipitation of Flag-HIF-1a
identified HA-FoxA2, but not HA-FoxA1, as an HIF-associated
protein (Figure 3E), consistent with the effect of FoxA2 but not
FoxA1 on HIF-dependent transcriptional activity (data not
shown). Importantly, endogenous FoxA2 was coprecipitated
with endogenous HIF-1a (Figure 3F) or HIF-1b (Figure 3G) in
TRAMP-C cells maintained under hypoxia. The association of
HIF-1b with FoxA2 was abolished following HIF-1a knockdown
(Figure 3G), indicating that HIF-1a recruits FoxA2 to the HIF
complex under hypoxia. Furthermore, in vitro binding between
purified His-FoxA2 and in vitro translated Flag-HIF-1a confirmed
their direct interaction (Figure 3H).ypes. Metastatic lesions are indicated by arrows.
ealed by IHC staining with indicated antibodies.
umber of mice and tissues examined: N = 32 (S2+/+ and S2+/), 16 (S2/), or
(S1a+/:S2+/) for lymph nodes. For each case, five serial sections of lung or
m TRAMP/Siah2+/ and TRAMP/Siah2/ mice.
RAMP/Siah2/ mice.
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Figure 3. FoxA2 Enhances HIF Transcriptional Activity
(A) TRAMP-C cells were transfected with an HRE-Luc construct and the indicated plasmids. Twenty-four hours after transfection, cells were maintained in 1%
oxygen for 10 hr, and cell lysates were collected to measure luciferase activity. b-Gal plasmid was used to normalize for transfection efficiency. N and H denote
normoxia and hypoxia, respectively. p < 0.01 pcDNA (N) versus HIF (N), p < 0.0005 HIF (N) versus HIF+FoxA2 (N).
(B) TRAMP-C cells were first transfected with indicated siRNAs and then 48 hr later with an HRE-luc construct. Twenty-four hours after the second transfection,
cells were maintained in 1% oxygen for 10 hr before analysis of luciferase activity. p < 0.005 for control (H) versus HIF-1a (H), HIF-1b (H), or FoxA2 (H).
(C) TRAMP-C cells were transfected with the FOXA-Luc construct and indicated FoxA2 deletion mutants. Twenty-four hours after transfection, cells were treated
with 1% oxygen for 10 hr before analysis of luciferase activity. p < 0.01 WT versus M-1, p > 0.1 WT versus M-2 or M-3.
(D) TRAMP-C cells were transfected with an HRE-Luc construct and the indicated plasmids. Twenty-four hours after transfection, cells were maintained in 1%
oxygen for 10 hr before analysis of luciferase activity. p < 0.001 HIF+WT (N) versus HIF+m3 (N). Each column in (A–D) represents mean ± SD of three replicates.
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Siah2, FoxA2, and HIF-1a in Prostate CancerIn vitro binding using truncation mutants of HIF-1a (Fig-
ure S2C) and FoxA2 (Figure S2B) identified the bHLH-PAS
domain of HIF-1a (Figure 3H) and the N-TAD of FoxA2 (Fig-
ure 3I) as the minimal regions mediating the HIF-1a-FoxA2 inter-
action. Although the bHLH-PAS domain of HIF-1a was found
to interact with FoxA2 and the PAS domain of HIF-1a is known
to interact with HIF-1b (Erbel et al., 2003), alternation of the
FoxA2 level in vitro or in TRAMP-C cells had no apparent effect
on the interaction of HIF-1b with HIF-1a (Figures 3J and 3K).
A Subset of HIF Target Genes Is Cooperatively
Regulated by FoxA2/HIF-1a
Transcript levels of the HIF targets VEGFA and Glut-1 were not
altered after FoxA2 expression or coexpression of HIF-1a and
FoxA2 in TRAMP-C, PC3, and HeLa cells (data not shown) sug-
gesting that FoxA2/HIF-1a cooperation selectively affects HIF-
regulated genes. We thus compared gene expression profiles
of TRAMP-C cells transfected with pcDNA control vector, or
expression vectors encoding FoxA2, HIF-1a, or HIF-1a plus
FoxA2. Approximately 140 genes in TRAMP-C cells were upre-
gulated by hypoxia (Table S2). Comparison of genes expressed
in each condition identified 47 genes upregulated in the HIF-1a +
FoxA2 group under hypoxia, in comparison with the other
three groups (Table S3). Of these and other hypoxia-induced
genes, we further assessed 30 genes for FoxA2-dependent
expression, selected based on prostate- and NE tumor-specific
expression. To confirm FoxA2-dependent transcription of this
gene set, we monitored changes in their expression in TRAMP-
C cells expressing FoxA2 siRNA. qRT-PCR analysis of selected
genes identified Hes6, Sox9, Jmjd1a, and Plod2 among those
that displayed FoxA2-dependent transcription under hypoxia
(Figure 4A).Sox9, Jmjd1a, andPlod2 are known HIF target genes
(Amarilio et al., 2007; Beyer et al., 2008; Hofbauer et al., 2003).
In contrast, transcription of Glut-1 and VEGFA was not altered
after FoxA2 knockdown (Figure 4A). Overall, these results sug-
gest that in TRAMP-C cells FoxA2 cooperates with HIF-1a to
regulate a subset of HIF targets under hypoxia.
HIF-1a and FoxA2 Cooperate to Activate
Hes6 Transcription
The transcription factor Hes6 is reportedly highly upregulated in
human metastatic prostate cancers with a NE phenotype (Vias
et al., 2008). Upregulation of Hes6 transcripts under hypoxia
suggests that Hes6 is a HIF target gene. Indeed, knockdown of(E) 293T cells were transfected with indicated plasmids. HIF-1awas precipitated w
itated proteins were analyzed by immunoblotting.
(F) TRAMP-C cells were maintained in 1% O2 for 5 hr. Endogenous HIF-1a was
(G) TRAMP-C cells were transfected with HIF-1a siRNA for 48 hr then maintained
proteins were analyzed by immunoblotting.
(H) HIF-1a and its truncation mutants were translated in vitro, labeled with 35S,
proteins on the beads were separated by SDS-PAGE and transferred to nitrocel
then immunoblotted with a His antibody to detect His-FoxA2. Four percent of in
(I) Flag-HIF-1a was translated in vitro and bound to the M2 beads then incubate
proteins were monitored as indicated in (H).
(J) TRAMP-C cells were stably transfected with indicated vectors and then grow
proteins were analyzed by western blotting.
(K) Flag-HIF-1a was translated in vitro and bound to the M2 beads then incubate
monitored as indicated in (H). See also Figure S2.HIF-1a reduced hypoxia-induced Hes6 transcription (Fig-
ure 4B). We identified three potential HREs and cloned the
corresponding 1.25 kb of the mouse Hes6 promoter region
upstream of a luciferase reporter. This construct was activated
2.5-fold by the hypoxia mimic DMOG (Figure S3A) and 1.8-fold
by hypoxia (data not shown). Deletion analysis of the Hes6
promoter revealed that the HRE at 66 bp was required for
hypoxia-induced reporter activity (Figure S3A). Mutation of this
HRE in the full-length 1.25 kb fragment resulted in loss of the
response to DMOG (Figure 4C). FoxA2 knockdown repressed
Hes6 transcription (Figures 4A and 4B), whereas FoxA2 overex-
pression increased Hes6 promoter activity after addition of
DMOG, an effect not seen using the HRE mutant promoter con-
struct (Figure 4D). These observations strongly suggest that
FoxA2-induced Hes6 promoter activity requires an HRE and
thus HIF activity. Chromatin immunoprecipitation (ChIP) con-
firmed that HIF-1a and HIF-1b bound the 66 bp HRE but not
the other two putative HREs in the Hes6 promoter under hypoxia
(Figure S3B). ChIP analysis confirmed the binding of FoxA2 to
the same 66 bp HRE, which was impaired following HIF-1a
knockdown (Figure S3C), suggesting that FoxA2 is recruited to
the promoter through HIF-1a. Similarly, FoxA2 bound to HRE-
containing promoter regions of Sox9 (Figure S3C) and Jmdj1a
(data not shown) in a HIF-1a-dependent manner. These results
indicate that FoxA2 regulates a subset of HIF target genes
possibly through direct binding to HIF.
FoxA2-Dependent Recruitment of p300
to the Promoters of HIF Target Genes
To analyze mechanisms underlying selectivity of FoxA2 cooper-
ation with HIF-1a, we investigated whether FoxA2 expression
changed HIF-1a levels, its asparagine hydroxylation, or its bind-
ing to the Hes6 promoter but found none (data not shown).
To directly assess the contribution of FoxA binding sites to
FoxA2/HIF-1a cooperation, we determined possible changes
in FoxA2/HIF-1a-mediated transactivation using Hes6 promoter
mutants (Figure S3D). While a single FoxA site was sufficient
to retain full responsiveness to FoxA2/HIF-1a cooperation, a
mutation within this element attenuated such cooperation (Fig-
ure S3D). Notably, analysis of the effect of FoxA2 on recruitment
of p300, a coactivator of HIF transcriptional activity (Arany et al.,
1996), revealed that binding of p300 to the Hes6 promoter
was attenuated after FoxA2 knockdown (Figure 4E). FoxA2
knockdown also reduced the binding of p300 to HRE-containingith Flag antibody-conjugated beads (M2) 48 hr posttransfection and the precip-
precipitated and coprecipitated proteins were analyzed by immunoblotting.
in hypoxia for 5 hr. Endogenous HIF-1b was precipitated and coprecipitated
and incubated with nickel beads coated with His-FoxA2. After three washes,
lulose membrane. 35S-labeled HIF-1a was detected by phosphor-imager and
vitro translated 35S-HIF-1a was used as input.
d with 35S-labeled in vitro translated FoxA2 or its truncation mutants. Bound
n in 1% O2 for 6 hr before immunoprecipitation of HIF-1a. The coprecipitated
d with 35S-labeled in vitro translated FoxA2 and HIF-1b. Bound proteins were
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Figure 4. A Subset of HIF Target Genes Are Regulated by Cooperation with FoxA2
(A) TRAMP-C cells were transfected with FoxA2 siRNAs. Forty-eight hours after transfection, cells were maintained in 1% oxygen for 10 hr and then RNA was
isolated for qRT-PCR analyses of the indicated transcripts. Control (H) versus FoxA2 (H): p > 0.1 for VEGFA and Glut-1, p < 0.005 for all others.
(B) TRAMP-C cells were transfected with indicated siRNAs. Forty-eight hours after transfection, cells were maintained in 1% oxygen for 10 hr. RNA was isolated
for qRT-PCR analyses of the Hes6 transcript. p < 0.05 between control (H) and HIF-1a (H), or FoxA2 (H).
(C) TRAMP-C cells were transfected with a 1.25 kbHes6 promoter-Luc construct containing the wild-type or mutated66 bp HRE. Twenty-four hours after trans-
fection, cells were treated with DMOG (1 mM, 16 hr) before analysis of luciferase activity. p < 0.005 for WT Hes6 –DMOG versus +DMOG, p > 0.1 for mutant
Hes6 –DMOG versus +DMOG.
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Siah2, FoxA2, and HIF-1a in Prostate Cancerpromoters of Jmjd1a and VEGFA in both TRAMP-C cells and
Rv1 cells (Figure 4F). However, p300 knockdown only reduced
the transcript levels of Hes6 and Jmjd1a but not VEGFA
(Figure 4G), which resembled changes seen upon knockdown
of FoxA2 (Figure 4A) on the hypoxia-induced transcription of
these genes. These results suggest that p300 serves a distinct
FoxA2-dependent HIF transcriptional program. Consistent with
this possibility, HIF-induced promoter activity of Hes6 was
more sensitive to increased p300 levels than that of VEGFA
(Figure 4H). Notably, p300, but not p300DCH1 (a p300 mutant
that cannot interact with HIF-1a), could further increase the
degree of HIF/FoxA2 effect on Hes6 promoter activity (Fig-
ure 4I). In contrast, FoxA2 and p300 showed no apparent effect
on HIF-dependent activation of the VEGFA promoter (Figure 4J).
These results suggest that recruitment of p300 is, in part,
responsible for the degree and the selectivity of the transcrip-
tional program elicited by HIF/FoxA2 cooperation.
In vitro protein binding showed that FoxA2 enhanced
HIF-1a/p300 interaction but had no effect on p300 binding to
the HIF-1a 531-822 mutant that cannot associate with FoxA2
(Figure S2C and Figures 3H and 4K). p300 lacking the CH1
domain neither interacted with the HIF/FoxA2 complex (Fig-
ure 4L) nor enhanced Hes6 transcription by HIF/FoxA2 (Fig-
ure 4I). These results suggest that FoxA2 promotes HIF and
p300 interaction unlikely require HIF-1a N-TAD and p300 CH3
domain (Ruas et al., 2010).
Genes Regulated by HIF/FoxA2 Are Important
for Tumorigenesis of TRAMP-C Cells
To determine whether genes regulated by HIF/FoxA2 coopera-
tion are important for tumorigenesis, we employed retroviral
vectors to re-express Hes6, Sox9, and Jmjd1a individually or
in combination in TRAMP-C cells stably expressing PHYL or
FoxA2 shRNA. While the endogenous expression of these genes
was attenuated upon expression of PHYL peptide or FoxA2
shRNA, their transcript levels were restored following ectopic
expression (Figures S4A and S4B). TRAMP-C cells expressing
control pBabe vector or NxN, a mutant PHYL that cannot
interact with Siah, but not those expressing PHYL or shFoxA2(D) TRAMP-C cells were transfected with indicated plasmids. Twenty-four hours a
luciferase activity. WT Hes6: p < 0.01 pcDNA-DMGO versus pcDNA+DMOG, p <
(E) TRAMP-C cells were transfected with control or FoxA2 siRNA. Forty-eight hou
of the HRE-containing region of Hes6 promoter were performed using indicated
A representative reversed gel image of triplicate experiments is shown.
(F) FoxA2 shRNA-expressing cells were treated with 1% oxygen for 6 hr and subj
were used for QPCR analyses of the HRE-containing regions of VEGFA, Jmjd1a
p < 0.01 for all genes between control and shFoxA2 for both cell lines.
(G) Cells were transfected with control or p300 siRNA for 48 hr and then analyze
control versus p300 siRNA for VEGFA and p < 0.05 for all others.
(H) TRAMP-C cells were cotransfected with Hes6 or VEGFA promoter-Luc vector,
cell lysates were collected for a luciferase assay. Hes6: p < 0.001 0 mg versus all
(I and J) TRAMP-C cells were transfected with Hes6 promoter-Luc (I) or VEGFA p
transfection, cell lysates were collected for analysis of luciferase activity. Hes6: p
HIF+FoxA2+p300; VEGFA: p > 0.1 for these comparisons. In (A)–(D) and (F)–(J),
(K) Flag-p300 was translated in vitro and coupled to M2 beads. HIF-1a or FoxA2
35S-FoxA2 were incubated with M2 bead-bound Flag-p300. Bound proteins wer
(L) Flag-p300 (wt or DCH1) was translated in vitro and bound to M2 beads. HIF
35S-HIF-1a and 35S-FoxA2 was mixed and incubated with M2 bead-bound Fla
Figure 3H. See also Figure S3 and Tables S2 and S3.could form colonies on soft agar (Figures 5A and 5B). Signifi-
cantly, coexpression of Hes6, Sox9, and Jmjd1a effectively
rescued the ability of TRAMP-C cells expressing either PHYL
or shFoxA2 to form colonies in soft agar but reexpression of
each individually was insufficient (Figures 5A and 5B). Consistent
with the effect of PHYL being Siah dependent, reduction of
Siah1a and Siah2 (Figure S4C) reduced levels of HIF-1a protein
(Figure S4D) and Hes6, Sox9, and Jmjd1a transcripts (Fig-
ure S4E), and attenuated the ability of these cells to form colo-
nies in soft agar under hypoxia (Figure S4F). The reduced ability
to form colonies in soft agar could be partially rescued upon
re-expression of Hes6, Sox9, and Jmjd1a (Figure S5F).
Similar to the findings in culture, control but not the PHYL-
expressing TRAMP-C cells were able to form tumors upon
injection into the prostate of mice (Figures 5C–5E). Whereas
re-expression of Hes6, Sox9, or Jmjd1a individually in PHYL-
expressing TRAMP-C cells failed to rescue tumorigenesis,
expression of all three was able to restore tumorigenicity (four
of five mice) and partially rescue tumor growth (30% of tumor
size) (Figures 5C–5E). Orthotopic injection of shFoxA2-express-
ing TRAMP-C cells into the prostate also showed significant
reduction in tumor formation, which was almost fully rescued
by coexpression of Hes6, Sox9, and Jmjd1a (Figures 5F and 5G).
These results further establish the importance of HIF/FoxA2
target genes, Hes6, Sox9, and Jmjd1a, in the development of
NE prostate tumor.
Genes Coregulated by HIF and FoxA2 Are Important
for Hypoxia-Associated NE Phenotype and Metastasis
of Human Prostate Adenocarcinoma Cells
We next assessed the importance of the pathway discovered
using the TRAMP model in human PCa. To this end, we selected
CWR22Rv1 cells (Rv1), which were derived from a human pros-
tate adenocarcinoma xenograft displaying an NE phenotype
(Huss et al., 2004; Sramkoski et al., 1999). Rv1 cells grown under
hypoxia showed upregulation of NE markers NSE and chromog-
ranin B (ChgB) (Figures 6A and 6B) and demonstrated protrusion
of neurite-like structures from cells located at the periphery of
colonies (Figure 6C). Concomitant with the induction of NEfter transfection, cells were treated with DMOG (1 mM, 16 hr) before analysis of
0.05 pcDNA+DMGO versus Foxa2+DMOG.
rs after transfection, cells were grown in 1% oxygen for 5 hr before ChIP assays
antibodies. PCR products were analyzed on 2% agarose gel electrophoresis.
ected to ChIP assays with p300 antibodies. The immunoprecipitated materials
, and Hes6. The results of ChIP QPCR were normalized to those of the input.
d by qRT-PCR for the indicated transcripts. Both TRAMP-C and Rv1: p > 0.1
HIF-1a, and increasing amounts of p300. Twenty-four hours after transfection,
three; VEGFA: p < 0.005 0 mg versus 0.5 mg, p > 0.1 0 mg versus the other two.
romoter-Luc (J) together with the plasmids indicated. Twenty-four hours after
< 0.01 HIF versus HIF+FoxA2, HIF versus HIF+p300, and HIF+FoxA2 versus
each column represents mean ± SD of three experiments.
was translated in vitro and labeled with 35S. Equal amounts of 35S-HIF-1a and
e monitored as indicated in Figure 3H.
-1a and FoxA2 were translated in vitro and labeled with 35S. Equal amount of
g-p300 or Flag-p300DCH1. Bound proteins were monitored as indicated in
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Figure 5. Hes6, Sox9, and Jmjd1a Are
Required for Tumorigenesis of TRAMPCells
(A) TRAMP-C cells were stably transfected with
indicated vectors. The inset shows a western blot
of PHYL and NxN. PHYL-expressing cells were
then infected with retroviral constructs encoding
Hes6, Sox9, or Jmjd1a individually or all together
(HSJ). Cells (1 3 105) were monitored for growth
on soft agar under 1% O2 for 3 weeks. Shown is
the number of colonies per well of six-well plate.
p = 0.4 (pBabe versus NxN), p = 0.053 (NxN versus
PHYL+HSJ), p < 0.0005 (NxN versus PHYL,
PHYL+Hes6, PHYL+Sox9, or PHYL+Jmjd1a),
p < 0.05 (PHYL+HSJ versus PHYL, PHYL+Hes6,
PHYL+Sox9, or PHYL+Jmjd1a).
(B) TRAMP-C cells were transfected with indi-
cated shRNA. The inset shows a western blot
of FoxA2. shFoxA2-expressing cells were then
infected with retroviral constructs of Hes6, Sox9,
or Jmjd1a individually or all together (HSJ). Cells
(1 3 105) were monitored for their growth on
soft agar under 1% O2 for 3 weeks. Shown is
the number of colonies per well of six-well plate.
p = 0.06 (pKLO.1 versus shFoxA2+HSJ), p <
0.005 (pKLO.1 versus shFoxA2, shFoxA2+Hes6,
shFoxA2+Sox9, or shFoxA2+Jmjd1a), p < 0.005
(shFoxA2+HSJ versus shFoxA2, shFoxA2+Hes6,
shFoxA2+Sox9, or shFoxA2+Jmjd1a). In (A) and
(B), each column represents mean ± SD for three
replicates.
(C–G) TRAMP-C transfectants (1 3106) as
described in (A) and (B) were injected into the
prostate of nude mice. Two months after injection,
genitourinary tracts of mice were dissected and
prostate tumor formation was quantified. (C)
shows the representative images of prostate
tumors, which were indicated by arrows. (D) and
(F) depict the frequency of tumor formation. (E)
and (G) show the average size of the tumors
formed. In (E) and (G), each column represents
mean ± SD for five mice. p < 0.05 pBabe versus
PHYL+HSJ and NxN versus PHYL+HSJ, p <
0.001 (pKLO.1 versus shFoxA2, shFoxA2+Hes6,
or shFoxA2+Jmjd1a), p < 0.005 (shFoxA2+HSJ
versus shFoxA2, shFoxA2+Hes6, or shFoxA2+
Jmjd1a), p < 0.01 (pKLO.1 versus shFoxA2+
Sox9), p = 0.2 (pKLO.1 versus shFoxA2+HSJ).
See also Figure S4.
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Siah2, FoxA2, and HIF-1a in Prostate Cancerphenotype was the upregulation ofHes6,Sox9, and Jmjd1a tran-
scripts (Figure 6D). Significantly, inhibition of Siah or knockdown
of FoxA2 attenuated hypoxia-induced upregulation of Hes6,
Sox9, and Jmjd1a (Figures S5A and S5B). To determine whether
Hes6, Sox9, and Jmjd1a are important for hypoxia-induced NE
phenotype, we re-expressed these genes individually or in
combination in PHYL- or shFoxA-expressing Rv1 cells (Figures
S5A and S5B) and found only coexpression of all three could
partially restore hypoxia-induced NSE upregulation and forma-
tion of neurite-like structures (Figures 6E–6G). These results
point to a requirement for Siah-HIF/FoxA2-regulated genes in
the hypoxia-induced NE phenotype of human prostate adeno-
carcinoma cells.
To evaluate the biological significance of NE phenotype for
human prostate cancer in vivo, we injected the above Rv1 trans-
fectants into the prostate of nude mice. Surprisingly, unlike32 Cancer Cell 18, 23–38, July 13, 2010 ª2010 Elsevier Inc.TRAMP-C cells, Rv1 cells expressing PHYL only showed about
30% reduction in the tumor size which could not be rescued
by coexpression of Hes6, Sox9, and Jmjd1a (Figure 6H). Simi-
larly, Rv1 cells expressing shFoxA2 did not exhibit any notable
decrease in tumor formation (Figure 6H). These results indicate
that Hes6, Sox9, and Jmjd1a are not involved in tumorigenesis
of Rv1 cells. The 30% reduction of tumor size by PHYL was
correlated with a 35% reduction in the tumor vessel density
(Figure S5C and Table S4) and 40% reduction of VEGFA tran-
script in PHYL-expressing Rv1 cells in vitro (Figure S5D). Simi-
larly, colony formation in the soft agar assay was comparable
for PHYL-expressing Rv1 cells and control cells (Figure S5E).
Significantly, the circulating PHYL- or shFoxA2-expressing Rv1
cells in the blood were reduced, indicating impaired intravasa-
tion of these cells, which was partially rescued by coexpression
of Hes6, Sox9, and Jmjd1a (Figure 6I). Although Rv1 cells
Cancer Cell
Siah2, FoxA2, and HIF-1a in Prostate Cancerexhibited limited ability to form liver metastasis (two out of ten
mice injected with Rv1 cells), they were very efficient in periaortic
lymph node metastases. Expression of PHYL or shFoxA2 abol-
ished lymph node metastases of Rv1 cells, which could be
largely restored by coexpression of Hes6, Sox9, and Jmjd1a
(Figure 6J). These findings suggest that genes coregulated by
HIF and FoxA2 play a key role in metastasis of prostate adeno-
carcinoma cells.
IHC analyses of Rv1 orthotopic tumors revealed that HIF-1a
and NSE staining were concentrated around the necrotic
regions, which are known to be highly hypoxic, whereas FoxA2
staining was evenly distributed (Figure 6K). As expected, expres-
sion of PHYL resulted in reduced HIF-1a staining and loss of NSE
staining in the hypoxic regions (Figure 6K). FoxA2 shRNA
reduced the NSE staining in the hypoxic regions without
affecting HIF-1a levels (Figure 6K), consistent with our in vitro
data (Figures 6E–6G). Importantly, consistent with our in vitro
results, coexpression of Hes6, Sox9, and Jmjd1a in PHYL- or
shFoxA2-expressing Rv1 cells restored the NSE staining in the
hypoxic regions (Figure 6K). Strong NSE staining was primarily
seen within the more hypoxic regions, proximal to the necrosis,
of the primary tumor (Figure 6K) and metastatic lesions in liver
and lymph nodes (Figure 6L), implying that the NE-differentiated
Rv1 cells may be responsible for the metastasis. These results
establish that genes coregulated by HIF and FoxA2 play a key
role in hypoxia-induced NE phenotype of PCa in vitro and
in vivo, and that NE phenotype is tightly associated with PCa
metastasis.
Expression of FoxA2-HIF-1a Target Genes in Prostate
Tumors
We next asked whether FoxA2/HIF-1a transcriptional targets
were expressed in NE tumors. The very few NE tumors identified
in a TRAMP/Siah2/ mice had lower transcript levels of Hes6,
Sox9, Jmjd1a, and Plod2 compared with TRAMP/Siah2+/-
derived NE tumors (Figure 7A), consistent with HIF-1a-depen-
dent expression.
The NE phenotype seen in human PCa can be classified to
three types based on IHC staining of NE markers (Cindolo
et al., 2007; Hirano et al., 2005; Shimizu et al., 2007): focal, in
which NE markers distinguish clusters of cells, found in low-
grade and moderately differentiated PCa; general staining, in
which larger tumor areas are positive for NE markers, found in
high-grade and poorly differentiated PCa; and single cells that
are stained positively for NE markers (Hirano et al., 2005). We
examined 15 cases of human PCa and found 10 to exhibit NE
phenotype. Two of the 10 samples displayed focal staining of
NE marker NSE, where FoxA2, Hes6, and Sox9 were concen-
trated in the NE foci (Figure 7B and Figure S6A). Eight of the
ten specimens showed a general staining of NSE, with costain-
ing of FoxA2, Hes6, and Sox9 in five of eight cases. Coexpres-
sion of FoxA2, Hes6, and Sox9 found in 70% of PCa specimens
with NE phenotype was statistically significant (p < 0.05;
Figure 7C).
We next performed IHC staining of a human prostate TMA
consisting of 79 cases representing prostatic intraepithelial
neoplasia (PIN) and different Gleason stages of PCa. A higher
NSE staining was found in high-grade PCa (G4 and G5), which
also showed increased staining of Siah2, FoxA2, Hes6, andSox9, compared with low-grade tumors (PIN and G3) (Figure 7D).
The difference in the expression of NSE, Siah2, FoxA2, Hes6,
and Sox9 between high-grade and low-grade tumors is statisti-
cally significant and correlated with pathoclinical staging. In
addition, IHC staining of three human prostate NE tumors
revealed coexpression of synaptophysin, FoxA2, HIF-1a, Hes6,
and Sox9 in all cases (Figure S6B). These findings suggest that
NE-positive tumors are associated with the more malignant
human prostate cancers, in which the HIF/FoxA2 target genes
are expected to play a role in the development of the NE pheno-
type. In agreement, gene expression data from human prostate
adenocarcinoma identified a marked increase in Hes6, Plod2,
Jmjd1a, and FoxA2 expression in metastatic prostate tumors,
compared with primary prostate tumors and normal prostate
tissues (Figure 7E). The expression of these genes correlates
with the expression of NE markers, further illustrating the link
between their expression, NED, and metastatic prostate tumors
(Figure 7E).
Whereas Siah2 staining was higher in high-grade PCa, HIF-1a
staining was found in both low-grade and high-grade tumors
(Figure 7D). Despite high level of HIF-1a expression in all grades
of tumors, the level of Glut-1, a common readout for HIF tran-
scriptional activity, was high only in high-grade PCa, pointing
to a correlation between Siah2 expression and HIF-1a activity
(Figure 7D). In agreement, gene expression analyses revealed
an increased Siah2 transcript and enhanced HIF activity in meta-
static PCa as reflected by increased transcript of HIF target
genes such as CA9, VEGFA, and Glut-1, compared with primary
PCa (Figure 7E). These results substantiate the correlation
between Siah2 expression and HIF activity in human PCa,
consistent with the role of Siah in regulation of PHD3 and
factor-inhibiting HIF-1 (FIH) stability, which control HIF-1a avail-
ability and activity (Nakayama et al., 2004; Fukuba et al., 2008).
The cooperation between HIF and FoxA2 in determining NE
phenotype can be attributed to a higher level of Siah2 which
increases HIF stability and activity, and availability of FoxA2 in
the high-grade PCa.
DISCUSSION
Our results provide insight into regulation and function of the
FoxA2/HIF-1a complex in determining NE prostate tumor forma-
tion and NE phenotype, an important component of metastatic
prostate adenocarcinomas. These results also point to a role
for Siah2 in determining tumor differentiation. Siah2 loss has
little effect on development and growth of the prostate luminal
epithelium but decreases initiation of NE carcinomas and,
consequently, the metastatic burden in the TRAMP model. We
show that partial deletion of Siah1a on a Siah2 null background
fully ablated NE tumor formation, suggesting that both Siah2
and Siah1 are required to enable the development of prostate
NE tumors.
As HIF-1a is stabilized under hypoxia and FoxA2 is
expressed in NE tissues, our findings suggest conditional and
spatial cooperation between these two factors under specific
tissue and oxygen requirements. Siah2-dependent regulation
of HIF coupled with NE-specific expression of FoxA2 pro-
vides a framework for a specific tumor differentiation program
associated with a highly metastatic phenotype. Among theCancer Cell 18, 23–38, July 13, 2010 ª2010 Elsevier Inc. 33
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Figure 6. Hypoxia-Induced NE Phenotype in Human Prostate Cancer Cells
(A) CWR22Rv1 cells were cultured under normoxia or hypoxia (1% O2) for indicated times before qRT-PCR analysis of NSE and ChgB. Transcript levels under
hypoxia were normalized to those under normoxia. p < 0.05, p < 0.005, p < 0.0001 for NSE hypoxia versus normoxia at days 1, 3, and 5, respectively. p = 0.19,
p < 0.005, p < 0.0001 for ChgB hypoxia versus normoxia at days 1, 3, and 5, respectively.
(B) Rv1 cells were grown under 1% O2 for indicated times. The total lysates were used for western blot analyses of NSE and ChgB. Hes6 and Sox9 were immu-
noprecipitated followed by western blot analysis.
(C) Rv1 cells were seeded onto the tissue culture plate at low density and cultured in 1% O2 for 6 days. Cells were fixed and immunostaind for NSE or ChgB.
Note the neurite-like protrusions from cells cultured under hypoxia.
(D) Rv1 cells were cultured under hypoxia for indicated times before qRT-PCR analysis. The transcript level under hypoxia was normalized to that of correspond-
ing normoxia samples. p < 0.005 for all three transcripts at all three time points.
(E) Rv1 cells were stably transfected with control pBabe vector or PHYL. In the inset, a western blot shows expression of PHYL. PHYL-expressing Rv1 cells were
further infected with viral constructs of Hes6, Sox9, or Jmjd1a either individually or in combination (HSJ). Cells were cultured under 1% O2 for 5 days before
qRT-PCR analysis of NSE. p < 0.01 pBabe versus PHYL+HSJ, p < 0.0001 pBabe versus all others, p < 0.005 PHYL+HSJ versus other PHYL-expressing cells.
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Cancer Cell
Siah2, FoxA2, and HIF-1a in Prostate Cancerfour FoxA2/HIF targets identified in this study, Hes6 is report-
edly highly upregulated in metastatic prostate cancers display-
ing NE markers (Vias et al., 2008) and Plod2 is overexpressed
in metastatic prostate NE tumors (Shah et al., 2004). Sox9
expression is increased in relapsed androgen-refractory pros-
tate cancers and is associated with enhanced growth, invasion
and angiogenesis (Wang et al., 2008). It is noteworthy that
Hes6, Sox9, and Jmjd1a have been shown to regulate differen-
tiation of stem/progenitor cells (Eun et al., 2008; Loh et al.,
2007; Nowak et al., 2008), raising the possibility that FoxA2/
HIF cooperation initiates a transcriptional program that regu-
lates neuroendocrine differentiation of normal and/or prostate
cancer stem cells. In agreement, the NE phenotype of PCa
is also associated with expression of the stem/progenitor
markers, supporting the notion that the NE-like cells may
harbor prostate cancer stem cells (Bonkhoff, 1998; Sotomayor
et al., 2009).
Several plausible mechanisms could underlie HIF-1a/FoxA2
transcriptional synergy; we ruled out that the intrinsic chromatin
remodeling activity of FoxA2 is important (Cirillo et al., 2002) and
that FoxA2 displaces HIF-1b. Our data implicate FoxA2 in
enhanced recruitment of p300 for the selective activation of
a subset of HIF-target genes. Consistent with our findings,
MEFs from mice expressing a p300/CBP mutant that cannot
interact with HIF exhibited attenuated HIF activity in luciferase
reporter assays, but they showed attenuated expression of
only a small subset of HIF target genes, not including VEGFA
and Glut-1 (Kasper et al., 2005).
The importance of Hes6, Sox9, and Jmjd1a for NE pheno-
type is demonstrated in human PCa cells that exhibit NE
phenotype under hypoxia. Inhibition of these genes attenuates
the NE phenotype and PCa metastasis, whereas their coex-
pression rescues the NE phenotype and metastasis even
upon knockdown of FoxA2 or Siah2, their upstream regulators.
Notably, the requirement of hypoxia for NE phenotype was
confirmed by IHC analyses of PCa in vivo where level of NSE
coincided with that of HIF, FoxA2, and their regulated genes.
Of equal significance, inhibition of mouse prostate tumor
growth by attenuating Siah2 activity could be overcome upon
coexpression of Hes6, Sox9, and Jmjd1a, further illustrat-(F) Rv1 cells were transfected with control pKLO.1 vector or FoxA2 shRNA. In the i
were further infected with viral constructs of Hes6, Sox9, or Jmjd1a either individu
qRT-PCR analysis of NSE. p < 0.05 pKLO.1 versus shFoxA2+HSJ, p < 0.0001 pKL
ing cells.
(G) Rv1 transfectants were seeded on tissue culture plates at low density and m
phase-contrast microscopy. The number of colonies with neurite-like structures
rite-like structure that is >20 mm long) were scored at triplicate of six-well plate
PHYL, p < 0.05 pKLO.1 versus shFoxA2 or shFoxA2+HSJ, p < 0.005 shFoxA2
for three replicates.
(H) Rv1 transfectants (1 3 106) as described in (E) and (F) were injected in
tumors were collected and size measured. p < 0.05 pBabe versus PHYL or
or shFoxA2+HSJ.
(I) Blood was collected from the heart of mice described in (H) before the sacrifice
plates was scored and normalized to the volume of blood. p < 0.01 pBabe versu
versus shFoxA2 or shFoxA2+HSJ, p < 0.005 shFoxA2 versus shFoxA2+HSJ. In
(J) Lymph nodes (LN) were collected from the mice described in (H) and stained w
PHYL), p = 0.17 (PHYL versus PHYL+HSJ), p < 0.01 (pKLO.l versus shFoxA2), p
(K) Orthotopic tumor sections as described in (H) were subjected to IHC staining
(L) The LN or liver metastasis from Rv1 orthotopic model was subjected to IHCing the importance of their cooperation for prostate tumor
development.
Overall, our study offers a paradigm underlying formation of NE
phenotype and NE prostate tumor development. This pathway
requires the ubiquitin ligase Siah2, which determines the level
and activity of HIF-1a, which then cooperates with the NE-specific
transcription factor FoxA2. It is the conditional and spatial regula-
tion of these factors that transactivates a subset of genes critical
for NE phenotype and metastasis of PCa as well as for develop-
ment of NE prostate tumors. Common to NE prostate tumors
and PCa harboring the NE phenotype is their strong propensity
to metastasize, and the poor outcome associated with these
more aggressive forms of prostate cancer. Our findings unveil
mechanisms underlying their development and progression,
respectively, while identifying possible targets for therapy and
markers for improved detection and monitoring of these tumors.
EXPERIMENTAL PROCEDURES
Prostate Tumor Samples
Prostate tumor samples representing NE tumors and/or prostate adenocarci-
nomas were obtained as part of approved clinical studies from the University of
California Davis (IRB #200312072), University of California Irvine (SPECS
project, IRB #20005-4806), and Northwestern University (SPORE tissue
banking protocol, IRB #NCI01X2: STU00009126). In all cases, informed
consent was obtained from all subjects.
Animal Studies
All animals were housed in the Sanford-Burnham Institute’s animal facility and
the experiments with live animals were approved by our institute animal
committee (IACUC #04-135, 04-141, 07-132) and conducted following the
institute’s animal policy in accordance with NIH guidelines.
Cell Lines
TRAMP-C cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% Nu-serum IV, 5% fetal bovine serum (FBS),
5 mg/ml insulin, and antibiotics. CWR22 Rv1 cells were maintained in
RPMI1640 medium with 5% FBS and antibiotics.
Generation of TRAMP Mice in a Siah2 Knockout Background
Siah2+/ mice (129 SVJ strain) were crossed with TRAMP transgenic mice
(C57/Bl6 strain) to obtain Siah2 heterozygotes carrying the TRAMP transgene
(C57/Bl6 and 129 SVJ mixed strain). Female Siah2+//TRAMP mice werenset, a western blot shows the knockdown of FoxA2. shFoxA2-expressing cells
ally or in combination (HSJ). Cells were cultured under 1% O2 for 5 days before
O.1 versus all others, p < 0.001 shFoxA2+HSJ versus other shFoxA2-express-
aintained at 1% O2 for 6 days. The morphology of cells was examined under
(criteria: greater than one-third of cells in the periphery of colonies have neu-
s. p < 0.01 pBabe versus PHYL or PHYL+HSJ, p < 0.001 PHYL+HSJ versus
versus shFoxA2+HSJ. In (A) and (D)–(G), each column represents mean ± SD
to the prostates of nude mice. Four weeks after injection, the orthotopic
PHYL+HSJ, p > 0.1 PHYL versus PHYL+HSJ and pKLO.1 versus shFoxA2
, cultured in the selection medium for 2 weeks. The number of colonies on the
s PHYL or PHYL+HSJ, p < 0.001 PHYL versus PHYL+HSJ, p < 0.05 pKLO.1
(H) and (I), each column represents mean ± SD for five mice.
ith H&E so that the metastases could be determined. p < 0.05 (pBabe versus
< 0.05 (shFoxA2 versus shFoxA2+HSJ).
of NSE, HIF-1a, and FoxA2.
staining of NSE. See also Figure S5 and Table S4.
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Figure 7. Changes in HIF/FoxA2 Targets in Prostate Tumors
(A) Laser capture microdissection was performed to collect NE carcinoma cells from tumors of TRAMP/Siah2+/ or TRAMP/Siah2/ mice. RNA was isolated for
qRT-PCR analyses of indicated transcripts. Each column represents mean ± SD for two replicates. Siah2+/versus Siah2/: p < 0.05 forHes6,Sox9, and Jmjd1a,
p = 0.78 and 0.46 for VEGFA and Glut-1, respectively.
(B) IHC of FoxA2, Hes6, and HIF-1awas performed on a human prostate adenocarcinoma with NED foci. Shown are representative images with a corresponding
NE control marker NSE.
(C) IHC staining using the indicated antibodies was performed on serial sections of 15 human PCa specimens, among which ten cases have NE phenotype (NSE
positive) and five cases have no NE phenotype (NSE negative). Coexpression of Hes6, Sox9, and Jmjd1a in human PCa with NE phenotype is statistically signif-
icant compared with that in human PCa without NE phenotype (p < 0.05).
(D) IHC staining of the indicated proteins was performed on a human prostate TMA consisting of PINs and prostate cancers of various Gleason scores; the
numbers of each tumor group are shown on the figure. The staining intensity is scored according to four scales by two pathologists: 0 (no staining), 1 (weak stain-
ing), 2 (medium staining), and 3 (strong staining). Scale 0 and 1 are defined as negative staining, and scale 2 and 3 are defined as positive staining. Shown is the
percentage of cores that are positively stained for indicated antibodies.
(E) Shown are clustered patterns of gene expression taken from GSE3325. Columns represent tumor samples (Benign, B1-B6; Primary, P1-P7; Metastatic,
M1-M6), and rows represent genes. The heatmap represents higher expression levels in red and lower levels in blue. Expression data for each gene were
row normalized. Transcript levels of Siah2, FoxA2, Hes6, Jmjd1a, Plod2, DDC, ChgB, and ENO2 in metastatic PCa are statistically significantly higher than those
in primary PCa. See also Figure S6.
Cancer Cell
Siah2, FoxA2, and HIF-1a in Prostate Cancercrossed with male Siah2+/mice to generate male TRAMPmice of three geno-
types (Siah2 +/+, +/, /), which were predominantly of the 129 strain. Female
Siah2+//TRAMP mice were also crossed with male Siah1a+/Siah2+/mice to
generate male TRAMP mice with a Siah1a+/Siah2/ genotype. Siah/TRAMP
mice were analyzed at 8 months of age.36 Cancer Cell 18, 23–38, July 13, 2010 ª2010 Elsevier Inc.Antibodies and Reagents
Antibodies to HIF-1a, HIF-2a, and Sox9 (NOVUS), to Hes6, Jmjd1a, p300, and
NSE (Abcam), to synaptophysin (BD Bioscience), to FoxA2, HIF-1b, and CD31,
Chromogranin B (Santa Cruz), to active caspase-3, Glut-1 (Chemicon), to
PCNA (Cell Signaling), to Siah2, FLAG, HA, a-tubulin, and b-actin (Sigma)
Cancer Cell
Siah2, FoxA2, and HIF-1a in Prostate Cancerwere used according to the manufacturers’ recommendations. An ApopTag
peroxidase in situ apoptosis kit was obtained from Chemicon.
Statistical Analysis
Student’s t test or Fisher’s exact test was used for the statistical analyses.
ACCESSION NUMBERS
Microarray data were deposited in the GEO database (GSE18478).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and Tables S1, S2, S3 and S4 and can be found online at doi:
10.1016/j.ccr.2010.05.024.
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